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Background: In vitro and clinical studies suggest that the oncogene LMP1 (latent membrane
protein 1) encoded by EpsteineBarr virus (EBV) plays a role in the development of
nasopharyngeal carcinoma (NPC) and the formation of metastases in immunocompetent
individuals. However, whether LMP1 itself is sufficient to drive these events in immuno-
competent hosts remains elusive due to the lack of appropriate experimental models. The
aim of this study was to study LMP1-dependent tumorigenesis and metastasis in BALB/c
mice inoculated with BALB/c-3T3 cells expressing N-LMP1 (a Taiwanese NPC variant).
Methods: Following cancer cell inoculation, metastasis formation was monitored over time
using PCR analysis of LMP1 as tumor marker. We also used a luciferase (Luc)-containing
N-LMP1 and bioluminescent imaging (BLI) to monitor metastasis formation in a non-
invasive manner.
Results: N-LMP1 appeared early in draining lymph nodes and in various distant organs
before the rapid growth of the primary tumor. Lung metastasis was observed by BLI andatory, Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung
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b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 2 6 1e2 7 1262further confirmed by histological examination. Furthermore, we detected luciferase signals
in the lungs, even before the animals were sacrificed.
Conclusions: Our results demonstrate the high metastatic character of N-LMP1 in immu-
nocompetent hosts. Systemic tumor dissemination occurs even before aggressive tumor
growth at the primary site, suggesting that early treatment of primary LMP1-associated
tumors and distant micro-metastases is critical to achieve positive results.At a glance commentary
Scientific background of the subject
EpsteineBarr virus (EBV)-encoded oncogene latent
membrane protein 1 (LMP1) has been shown to play a
role in the metastasis of nasopharyngeal carcinoma
(NPC), an EBV-associated cancer that uniquely develops
in immunocompetent individuals. We sought to
examine whether and when LMP1 drives the formation
of spontaneous metastasis in the immune intact host
using a mouse tumor model established by N-LMP1, a
LMP1 variant isolated from Taiwanese NPC patients.
What this study adds to the field
The primary tumor initiated by N-LMP1 showed high
metastatic potential in the immunocompetent host.
Systemic tumor dissemination occurred immediately
after angiogenic switch but before aggressive tumor
growth at the primary site. This finding suggests a crit-
ical time window for LMP1-based therapeutic in-
terventions that could be used to concomitantly treat
primary tumor and distant metastases.Cancer is a leading cause of death worldwide and survival
rates rapidly decline once metastases occur [1]. Metastasis
development is a multi-step process characterized by the
invasion-metastasis cascade [2e4]. This process involves
cancer cell invasion into surrounding tissues, intravasation
into nearby blood vessels, passage into the circulation, fol-
lowed by homing into distant tissues, formation of newmicro-
metastasis foci which eventually grow to form macroscopic
secondary tumors. Tumor cell lines have been used to study
the growth and motility of cancer cells following their inocu-
lation into the tail vein of mice [5e7]. The role of the micro-
environment is becoming more and more important in the
study of factors regulating metastasis formation [8]. Unfortu-
nately, in vitro cell culture does not reflect the importance of
the microenvironment, nor does intravenous tail vein
administration simulate the natural course of spontaneous
metastasis. Therefore, establishing a spontaneous metastasis
mouse model is of paramount importance in the study of
tumor metastasis.
Bioluminescent imaging (BLI) has been recently developed
to facilitate in vivomonitoring of cellular processes in various
pathophysiological conditions [9e11]. BLI is a non-invasive
imaging technique involving the generation of cold light by
luciferase-expressing cells in animals following administra-
tion of luciferin substrate. Cold-light signals are then imagedusing an external detector, allowing dynamic visualization of
tumor-associated properties in living animals.
Nasopharyngeal carcinoma (NPC) is amalignant retronasal
tumor that is endemic in Southern Asia and Taiwan [12].
Expression of the oncogene LMP1 (latent membrane protein 1)
encoded by EpsteineBarr virus (EBV) has been associated with
NPC pathogenesis [13]. NPC arises in immunocompetent hosts
despite active humoral and cellular responses against EBV
antigens at the systemic level [14]. Metastasis of NPC to
regional lymph nodes and distant organs has been docu-
mented [15]. In clinical studies, LMP1 has been detected in
local lymph nodes and distant tissues containing NPC
metastasis by using immunohistochemistry. The cumulative
metastasis rate has been estimated at 66.8% (269/403) in cases
associated with LMP1 expression and 47.0% (148/315) in those
where LMP1 expression is absent [16]. However, other studies
have failed to demonstrate a link between LMP1 expression
and the degree of tumor metastasis [17e19]. To date, metas-
tasis development remains a problem in NPC treatment, and
there are currently few animal models available to study
spontaneous metastases in immunocompetent mice.
The cancer cell transformation role of LMP1 was initially
described in a B-lymphoma, called B-LMP1 [20]. Later, LMP1
variants with a 30-nucleotide deletion at the 30-end of the gene
along with point mutations within the gene were observed in
Chinese NPC [21,22]. The variant isolated from NPC patients in
Taiwan, designated N-LMP1, shows the 30-nucleotide deletion
but mutations at different regions than the ones identified
previously [23]. In contrast to the prototype B-LMP1, N-LMP1-
transfected BALB/c-3T3 cells (3T3/N-LMP1) exert a more
potent oncogenic activity and form solid tumors in nude mice
[24]. Studies have shown that N-LMP1 downregulates the
expression of cell adhesionmolecules; upregulates the activity
ofmatrixmetalloproteinases1and9;and increasescellmotility
[25,26]. Furthermore, the invasive and metastatic potential of
NPC cells is induced by N-LMP1 expression, and is inhibited
when LMP1 expression is abrogated using small hairpin RNA
in vitro and in immunodeficientmice [27,28]. However,whether
tumor cells expressing N-LMP1 alone may metastasize in
immunocompetent individuals has not been examined so far.
One characteristic of NPC is the massive leukocyte infil-
tration observed in tumor tissues [29], suggesting a role for
components of the immune system in tumor pathogenesis. To
study the contribution of immune cells in N-LMP1-driven
oncogenesis, we previously established an N-LMP1-derived
tumor model in syngeneic immunocompetent mice using
tumorigenic 3T3/N-LMP1 cells [30]. Using this model, we
report here the possibility to track tumor metastasis by using
PCR analysis of N-LMP1 as tumor marker. Furthermore, we
show that BLI can be used to follow the occurrence of spon-
taneous N-LMP1-derived tumor metastasis in immunocom-
petent hosts.
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 2 6 1e2 7 1 263Methods
Mice
BALB/c and severe combined immunodeficiency (SCID) mice
were purchased from the National Laboratory Animal
Breeding and Research Center (Taipei, Taiwan) and BioLASCO
(Ilan, Taiwan), respectively [30]. 6e10-week old mice were
used in the experiments reported here. Animals were main-
tained in strict accordance with the NIH Guide for the Care
and Use of Laboratory Animals, and animal experiment pro-
tocols were reviewed and approved by the Animal Ethics
Committee of Chang Gung University.
Cell lines and N-LMP1 tumor model
The 3T3/N-LMP1 cell line (stable clone E2) established previ-
ously [23] was maintained at 37 C in Dulbecco's modified
Eagle's medium (DMEM) containing 10% fetal bovine serum
(FBS). The N-LMP1 tumormodel used in the present studywas
described earlier [30]. In brief, 3T3/N-LMP1 cells were injected
into SCID mice to induce tumors. Tumor fragments of the
initial tumor were transferred into BALB/c mice by subcu-
taneous transplantation. Subsequently, tumor lines were
passaged in vivo in BALB/c mice every 3e4 weeks. The day of
transplantation was designated as day 0. Tumor volume was
determined using the following formula:
volume ¼ width  length  height  0.52. The same strategy
was used to establish the bioluminescent E2-Luc model using
E2-Luc tumor cell line (see below).
Polymerase chain reaction (PCR)
Genomic DNA was extracted from different animal organ and
tissues. The primers, PCR reaction conditions and gel electro-
phoresis forN-LMP1 and internal control GAPDHweredescribed
previously [30,31]. N-LMP1 primers: sense primer (50-
GGTTGATCTCCTTTGGCTCCTCCTG-30) andantisenseprimer(50-
GTCAGTCAGGCAAGCCTATGACATG-30). GAPDH primers: sense
primer (50-TGGTATCGTGGAAGGACTCATGAC-30) and antisense
primer (50-ATGCCAGTGAGCTTCCCGTTCAGC-30). Luciferase
primers: sense primer (50-TCAAAGAGGCGAACTGTGTG-30) and
antisense primer (50-GGTGTTGGAGCAAGATGGAT-30).
Establishment of E2-Luc stable cell line
A 2.5-kb fragment containing the complete coding region of
luciferase-EGFP was released from the pL3-TRE-LucGFP-2L
plasmid (Addgene, Cambridge, MA, USA) by SacIl and EcoRV
double digestion. The DNA fragment was then ligated into a
lentiviral vector, pLenti 6.2 (Life Technologies), designated
pLenti-LucEGFP [32]. A lentivirus carrying LucEGFP was used
to transduce E2 cells. GFP/Luc-infected E2 cells (E2-Luc) were
trypsinized and washed with phosphate-buffered saline (PBS)
and put on ice. To collect GFP-positive cells, the isolated E2-
Luc cells (1  106) were resuspended in 500 ml PBS and GFP-
positive cells were sorted using a FACScan ﬂow cytometer
(Becton Dickinson, CA, USA). Fluorescence emission for GFP
was determined at 530 nm (FLI). Acquisition was performedautomatically using the CellQuest Pro software (Becton
Dickinson).
To enrich Luc image, virus-infected E2 cells (carrying the
EGFP-Luc plasmid) were grown for 14 days in vitro and sub-
jected to two rounds of cell sorting against EGFP. The first
sorted cells were grown for 12 days in vitro before the second
sorting. The LMP1-positive cells enriched by cell sorting were
used for animal experiments.
MTT assay
Cell viability was determined using the 3-(4,5-
dimethylthiahiazo-2-yl)-2,5-di-phenytetrazoliumromide
(MTT) colorimetric assay. Briefly, E2 or E2-Luc cells (103) were
cultured in 96-well plates. The culture medium (100 ml) was
changed on day 3 and 5. MTT solution (0.5 mg in PBS) was
added into the wells and incubated for 4 h. Supernatants were
collected and formazan was dissolved with 150 ml of DMSO,
following reading at a wavelength of 570 nm.
Anchorage-independent colony forming assay
The anchorage-independent growth of E2 and E2-Luc cells was
assessed by soft-agar colony formation assay. Cells (1.5  103)
were resuspended in 3 ml of DMEM containing 10% FBS and
0.7% agar and added over a layer of 5 ml of the same medium
containing 1% agar in 6-well culture plates. Three-weeks later,
colonieswere stainedwith a solutionof 0.04% crystal violet and
2% ethanol in PBS. Photographs of the stained colonies were
taken and colony numbers were counted.
Transwell assay
Transwell plates with a membrane filter (6.5 mm diameter,
8 mm pore size; BD Biocoat, New Jersey, NJ, USA) were used to
measure cell migration. The upper chamber contained either
E2 or E2-Luc cells in serum-free medium (8  104/100 ml), and
the lower chamber contained 600 ml of FBS-containing me-
dium. Twenty hours later, cells left on the upper surface of the
membrane were scraped with a cotton swab. Cells on the
bottom membrane surface were stained with a crystal violet
solution and counted under the microscope.
In vitro bioluminescence assay
E2-Luc cells were permeabilized by luciferase cell lysis buffer
(Promega,WI,USA) and the protein extractwas quantifiedusing
the SpectraMax 340PC384 ELISA reader (Molecular devices, CA,
USA). Bioluminescent intensity was then measured by mixing
25 mg of protein with 100 ml luciferin (Beta-Glo Assay System,
Promega) using Dual-Luciferase Assay System (Promega).
In vivo bioluminescence assay
Mice bearing subcutaneous E2-Luc tumors were injected intra-
peritoneallywith the luciferasesubstrateD-luciferin (125mg/kg,
Sigma). Mice were placed in a dark chamber of the IVIS 100 im-
aging system (Xenogen, Alameda, CA, USA) under isoflurane
anesthesia. Photographic and bioluminescent images (BLI) were
captured according to themanufacturer's instructions.
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Tumor specimens and mice organs were fixed in 10%
formalin, embedded in paraffin and sectioned for light mi-
croscopy. Tumor sections (5 mm) were stained with hema-
toxylin and eosin (H&E) as described [30].
Statistical analysis
Data analysis was performed using the Microsoft Excel
software. Student t-test was used in the experiments. The
values presented are expressed as mean ± standard devia-
tion (SD). A level of 0.05 was considered to be statistically
significant.Results
Dissemination potential of N-LMP1-expressing cancer cells
N-LMP1 is the prevalent LMP1 variant in Taiwanese NPC pa-
tients [21,23]. Previous studies have demonstrated that 3T3/N-Fig. 1 e Potential of E2 tumor metastasis. (A) The presence of N-LM
from E2 tumor-bearing SCID mice at the indicated time points (N
(white circle) PCR signals from (A) are shown.LMP1 cells (e.g., clone E2) can form tumors in syngeneic
immunocompetent mice following subcutaneous trans-
plantation of tumor fragments derived from nude (or SCID)
mice. In this model, tumor development occurs during the
first two weeks, but exponential growth occurs during week
2e3 [30]. By using non-invasive dynamic contrast-enhanced
magnetic resonance imaging, we have identified an angio-
genic switch period between days 7e14 prior to rapid tumor
expansion [33]. To further characterize whether and when N-
LMP1 tumors disseminate, we examined the presence of LMP1
DNA in various tissues on day 5e28 using PCR analysis. To
ensure the detection of tumor cells homed to (instead of
temporarily passing by) the tissues [34,35], tumor-bearing
mice were perfused with PBS before removing organs for
DNA extraction. N-LMP1 DNA was detected in draining lymph
nodes as early as day 7 [Fig. 1]. N-LMP1 DNAwas also detected
in the thymus and spleen in somemice at day 15e17. N-LMP1
DNA signal was also detected in the liver and lungs. After day
15e17, the signal remained high in the lymph nodes, liver,
lungs and thymus. These results indicate that dissemination
of N-LMP1 tumor cells to draining lymph nodes occurs early
(within 7 days) following tumor formation.P1 DNA was identified by PCR assay in the indicated organs
¼ 3 or 6). (B) Organs with positive (black circles) or negative
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We next sought to establish a Luc-bearing E2 tumor model, in
an attempt to visualize in a non-invasive manner the devel-
opment of micro- and macro-metastases after cancer cell
dissemination. We used an animal model based on a Luc-
positive 3T3/N-LMP1 cell line as described earlier [30].Fig. 2 e Establishment of E2-Luc cell line. (A) GFP/Luc-tranduced E2
collection of GFP positive cells by flow cytometry. (B) E2-Luc cell
growth was estimated using the MTT assay (C) and soft agar assay
and quantitative analysis is shown in (F). E2-Luc cells were not st
growth and cell migration results. Data represent means ± SD.Accordingly, E2-Luc cells were enriched by flow cytometry
[Fig. 2A, see Method for details]. The GFP-positive cell fraction
only represented 66.55% of the cell population before sorting
but reached 91.75% and 95.27% after the first and second
sorting steps, respectively. The E2-Luc cell line exerted stable
luciferase activity, giving a luciferase intensity between
60e120  106 over 25 passages (Fig. 2B). To understandcells underwent two (D14 and D26) cell sortings based on the
line showed stable luciferase activity over 25 passages. Cell
(D). Cell migration was analyzed using the transwell assay (E)
atistically different than parent E2 cells in terms of both cell
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 2 6 1e2 7 1266whether the luciferase/eGFP plasmid affected the cells, we
compared the growth of E2 and E2-Luc cells using the MTT
assay (Fig. 2C). In addition, the tumorigenic and invasive po-
tentials of the cells were examined using respectively the soft
agar assay (Fig. 2D) and transwell migration assay (Fig. 2E,F).
The tumorigenic and invasive potentials of E2-Luc cells and
parental E2 cells were similar, indicating that luciferase/eGFP
transfection did not alter cellular functions.
Luciferase activity of E2-Luc tumors in SCID mice
In vivo tumorigenicity of E2-Luc cells was examined by
injecting the cells subcutaneously into SCID mice. The for-
mation of Luc-positive tumors was monitored between week
1e4 using the BLI system [Fig. 3A]. Tumor growth was quan-
tified by measuring luciferase intensity as a function of time
(Fig. 3B). E2-Luc cells demonstrated strong tumorigenicity as
seen by the formation of palpable tumors two weeks after
induction, with continuous growth occurring between week
2e4.
Partial loss of luciferase activity of E2-Luc tumors in BALB/c
mice
To induce E2-Luc tumor formation in BALB/c mice, tumor
fragments derived from tumor-bearing SCID mice (mouse #3
in Fig. 3) were transplanted into BALB/c mice [Fig. 4A]. As
persistent expression of luciferase activity in the tumor mass
is a critical feature for a usable animal model, we examined
the duration of the luciferase signal in transplanted tumors
in vivo. Surprisingly, while the luciferase signal of E2-Luc tu-
mors was detected at day 7 following transplantation in BALB/
c mice, the signal was entirely lost at day 42 (Fig. 4A and B). No
luciferase activity was detected in the region of E2-Luc tumorsFig. 3 e Tumor growth and BLI signal quantification of E2-Luc tumo
in the back of mice (numbered 1e6) at day 1. BLI was performed
tumors was quantified at the indicated days. Data represent meain which light signal was lost (Fig. 4C, dark region), although
luciferase DNAwas still detected by PCR in both the bright and
dark tumor regions (Fig. 4D). These results suggest that lucif-
erase expression was dramatically suppressed in trans-
planted E2-Luc tumors. Besides, we observed that tumor
growthwas similar in BALB/c and SCIDmice (data not shown).
Together, these results suggest partial loss of luciferase ac-
tivity of E2-Luc tumors in BALB/c mice.
Establishment of a stable E2-Luc tumor line by successive
in vivo passages from the luminescence-positive tumor
fragments of BALB/c mice
To access whether the E2-Luc cancer cell line can consistently
express luciferase, we transplanted fragments of luciferase-
positive bright tumor tissues from BALB/c mice (mouse #3 in
Fig. 4, was assigned as passage 0, labeled as P0) into 5 naive
BALB/cmice, followed by a series of in vivo passages from P0 to
P4. BLI observation was performed at the days indicated
[Fig. 5A]. Luciferase intensity of different passages (P1e4) tu-
mors from was also quantified (Fig. 5B). Tumor growth of
different passages, including of E2 parental tumors and E2-Luc
tumors P0e4, was measured (Fig. 5C). BLI images showed that
early passages (P0, P1, P2) still contained the tissues that had
lost luciferase activity, and the tumor growthwas slower than
parental E2 tumors. Luminescent areas and tumor growth
increased in later passages (P3, P4), approaching the levels
observed for parental E2 tumors.
Identification of lung metastasis derived from E2-Luc
tumors in BALB/c mice
To assess systemic metastasis dissemination, mice of pas-
sages 0e7 (P0eP7) were sacrificed at day 28. Local tumors andr in SCIDmice. (A) E2-Luc cells were subcutaneously injected
on day 7, 14, 21, and 28. (B) Luciferase intensity of 6 mouse
ns ± SD.
Fig. 4 e Tumor growth and BLI signal loss in E2-Luc tumors in BALB/c immunocompetent mice. Fragments of E2-Luc tumors
from SCID mice (#3 mouse in Fig. 3) were transplanted into BALB/c mice (numbered 1e5). (A, B) BLI was performed at day 7 and
day 42 and luminescence signals were detected and quantified. Data are presented as mean ± SD. (C) There was no luciferase
activity in the loss light signal region (dark region) of E2-Luc tumors in BALB/c mice. The E2-Luc cell line showed luciferase
activity as positive control and E2 cell as negative control. (D) The presence of luciferase DNA in the bright or dark tumor
regions was identified by PCR assay. The E2 cell line was used as negative control and E2-Luc as positive control. GAPDH was
used as internal control.
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were removed to perform ex vivo BLI [Fig. 6A,B], followed by
histological examination. Luciferase activity was detected in
local tumors, predominantly in the lungs and some lymph
nodes, implying that E2-Luc tumors could progress to form
metastases which could be detected ex vivo at thewhole tissue
level. By using H&E staining, we observed that the majority of
lung tissue sections harbored metastatic tumor nodules, as
exemplified here by a P7 mouse (Fig. 6C). Concordance be-
tween BLI signals the presence of N-LMP1 DNA was further
verified by PCR analysis (Fig. 6D). N-LMP1 DNA could be
detected in the corresponding tissues of the tested mice,
mainly in the lungs. Although N-LMP1 DNA and/or BLI was
detected in some other organs such as lymph nodes and liver,
no pathological tumor nodules could be found (data not
shown), suggesting that the lung is the preferential target
organ for N-LMP1 tumor metastasis in this animal model. As
metastasis usually involves a low number of cells colonized in
internal organs, prolonged exposure may be required. In this
animal model, we found that the internal metastatic organsrequire an exposure time of at least 30 s. Since local primary
tumors show much more luminescence intensity, distant
organ metastasis with relatively low luminescence signal will
be overwhelmed by a strong local tumor luminescence signal,
making it impossible to explore tumor metastasis. To over-
come this problem, we shielded the strong luminescence
signal of tumors by using black card. In vivo BLI image lucif-
erase activity from lung-like regions could be detected directly
(red circle, Fig. 6E, left panel). Together with the ex vivo BLI
images of the lungs, liver, spleen, thymus, and lymph nodes
observed after in vivo BLI, only the lungs could be shown to
produce a positive signal (Fig. 6E, right panel).Discussion
The metastasis-inducing character of LMP1 has been sug-
gested in various in vitro and clinical studies [15,25]. However,
whether the expression of LMP1 alone in cancerous cells could
lead to the formation of distant metastases in
Fig. 5 e A stable in vivo E2-Luc tumor line was established by
series of in vivo passages from the luciferase-positive bright
tumor tissue of BALB/c mice (#3 mouse in Fig. 4, was
assigned as passage 0, P0). Luminescence-positive tumor
tissues were transplanted from passage 1e4 (P1e4). BLI
images were obtained (A) at the indicated days. Arrows
indicated the mouse was selected for tumor transplantation.
(B) Luciferase intensity of different passages (P1e4) tumors
from (A) was quantified. (C) The tumor growth curve of
different generations (E2 parent tumor, E2-Luc tumor P0e5)
was shown on. Data represent means ± SD.
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study, a tumor model system that we established previously
[30] was simplified to highlight the interaction between N-
LMP1 and the immune system during tumor progression. By
using this system, our results demonstrate early systemic
dissemination and natural lung metastasis formation from
primary N-LMP1 tumors, suggesting that N-LMP1 may be
involved in both tumor initiation and metastasis formation in
spite of an intact host immune system.
Our data suggest that N-LMP1 tumor cells could spread to
the draining lymph nodes at an early time. This finding is
consistent with previous clinical studies that observed prox-
imal metastasis of regional lymph nodes in the early stage of
NPC development [36,37]. Moreover, our results also indicate
that the dissemination to distant organs occurs before the
rapid growth of primary tumors, supporting the emerging
notion that tumor cell disseminationmay take place early and
that it may not necessarily be a late event during cancer
progression [4,38e40]. While primary tumors undergo angio-
genic switch at days 7e14 [33], the appearance of LMP1 in
distant organs at days 15e17 implies that dissemination can
occur as soon as tumor neovasculature is established.
Although bone metastasis of NPC in clinical cases is frequent
[36], LMP1 in bone marrow was not detected in our model
system (see Fig. 1B). As the microenvironment at the primary
tumor site is believed to play an important role for the for-
mation of distant metastases [7,41], the lack of bone dissem-
ination may suggest that N-LMP1 alone is insufficient to
influence this specific site. Other viral and host factorsmay be
essential for bone marrow dissemination [41e43]. Alterna-
tively, because the experimental cell line used in this study is
a 3T3/N-LMP1 cell line which is different from the epithelial
nature of NPC, the microenvironment might not be important
for 3T3 cell lodging into the bone marrow.
In this study, a bioluminescent N-LMP1 tumor model was
established for the assessment of spontaneous metastasis
formation. As suggested by in vitro and in vivo analyses, the
high carcinogenicity of E2 cells was stably maintained in E2-
Luc cells and the luminescence intensity showed positive
correlation with tumor growth in SCID mice. However, when
tumors were transplanted into BALB/c mice, BLI signal
declined with time. Several factors may explain the disap-
pearance of luminescence intensity. One possibility is that the
luciferase gene still existed, but was suppressed by host fac-
tors (such as cytokines), which can inhibit the CMV promoter
that drives luciferase expression [44]. PCR detection of the
dark tumor area which showed no luminescence activity
indicated that luciferase gene indeed still existed (Fig. 4D),
implying that its expression may have been down-regulated
by the immunocompetent host. Furthermore, since both GFP
and luciferase are foreign protein antigens which possibly
bear immunogenicity, it is possible that E2-Luc cells down-
regulated luciferase expression to avoid host immune de-
fense. Nonetheless, we established a stable E2-Luc tumor line
of BALB/c mice by a series of in vivo passages from the
luciferase-positive tumor graft.
BLI observations in BALB/c host suggested a high proba-
bility of metastasis in the lungs and lymph nodes (Fig. 5B),
Fig. 6 e Metastasis of E2-Luc tumor in BALB/c mice. Mice of passages 0e7 (P0eP7) were sacrificed at day 28. Local tumor and
various organs were removed to perform BLI ex vivo (A, B) followed by histological examination (C). (A) Representative ex vivo BLI
images of lungs, spleen, liver, lymph nodes, and thymus. Lung and lymph nodes were shown with positive signals. (B) Organs
with (black circles) or without (white circles) luminescence from (A) are shown. (C) Representative H&E-stained tissue sections
of positive BLI region showed only lung tissues with tumor nodules. (D) The presence of LMP1 DNA in the indicated organs of
E2-Luc tumor-bearing mice was detected by PCR assay at day 21 in an independent experiment. Organs with positive (black
circles) or negative (white circles) PCR signals are indicated. (E) Representative in vivo BLI images revealed metastatic E2-Luc cell
luciferase activity in lung tissues. The strong luminescence signal of the local primary tumor was shielded by black card (the
red circle on the mouse indicated that BLI signal originated from lung-like regions).
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 2 6 1e2 7 1 269indicating that after systemic dissemination only few distant
sites could proceed into metastasis. H&E stained tissues
showed that lung tumors were indeed present, suggesting
possible E2-Luc cell colonization, but with no signs of tumormetastases to other organs. It is possible that early dissemi-
nation of tumor cells to the lymph nodes (day 7) may remain
dormant at low cell numbers, being unable to successfully
colonize the immunocompetent microenvironment.
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 2 6 1e2 7 1270The in vivo BLI system is based on the relationship be-
tween the detection sensitivity and cell numbers. Our ulti-
mate goal was to visualize tumor progression (local and
metastasis) non-invasively by keeping animals alive for lon-
gitudinal imaging. As metastasis usually involves low num-
ber of cells colonized in the internal organs, prolonged
exposure time is required to obtain tumor image. In this
model, we found that the internal metastatic organs require
an exposure time to at least 30 s. In this situation, the local
primary tumor is much more luminescent than the metas-
tases. Distant organ metastasis with relatively low lumines-
cence signal will be overwhelmed by a strong local tumor
luminescence signal, making it impossible to explore tumor
metastasis. Nevertheless, by using a shield of black card-
board and BLI observation from the side of animals, lumi-
nescence from the lung region could be detected. Although
some of our objectives could not be achieved due to technical
limitations, the luminescent N-LMP1 tumor model could still
serve as a powerful screening tool for ex vivo tracking of
tumor metastases in future studies.
In this study, no metastatic tumors were observed in
the bone marrow. Since the experimental cell line used in
this study is 3T3/N-LMP1 which is different from the
epithelial nature of NPC, it is possible that the microen-
vironment is not important for 3T3 cell lodging in the bone
marrow. We noted that a NIH3T3 fibroblast-derived cancer
cell produced by LMP1 expression may not be truthfully
representative of LMP1-transformed epithelial cancer as
LMP1-associated NPC. Although this model can not be used
to fully explain oncogenesis and metastasis of epithelial
tumors like NPC, our results still demonstrated the high
metastatic character of N-LMP1 in immunocompetent
host. Our results also showed that systemic cancer cell
dissemination could occur before the aggressive tumor
growth of at the primary site. In addition, due to the fact
that tumor cells are implanted directly into the organ of
origin, these tumors reflect the original situation (e.g., the
microenvironment) much better than conventional sub-
cutaneous tumor models. It will be more realistic if these
results can be verified by taking orthotopic tumor models
rather than standard subcutaneous models. Nevertheless,
the results of this study may reveal critical insights
applicable to clinical settings.
Taken together, our results demonstrate the high potential
of early systemic dissemination and metastasis of N-LMP1-
expressing primary tumors. The study of spontaneous
metastasis may better reflect the development of metastasis
occurring in vivo; our system can therefore be used as a plat-
form for the study of future cancer therapeutics targeting
LMP1 in NPC. In particular, our study shows the precise timing
of multi-organ spreading with tumor angiogenic transition
[45], suggesting a critical timewindow to treat primary tumors
and distant metastases.Conflicts of interest
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